ArticleThoracic cancer2022
Lymphovascular invasion: A non-sized T descriptor for stage IA non-small cell lung cancer.
Article in Thoracic cancer, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed.
- An interpretable multi-task whole-slide histopathology AI model for non-small cell lung cancer: Cross-cohort generalisation, spatial attention-transcriptomic integration, and molecular-immune profiling.Clinical and translational medicine · 2026Article
- Prognostic impact of invasive features in completely resected NSCLC stratified by tumor diameter.Journal of cardiothoracic surgery · 2026Article
- Article
- Integrated PET-IVIM-DKI MRI for predicting lymphovascular invasion in NSCLC.Insights into imaging · 2025Article
- Prognostic Factors and Survival Data of Stage I Lung Cancer: A Single-Center Experience.Journal of clinical practice and research · 2025Article
- Development and validation of models based on clinical and CT features: multivariate analysis for predicting vascular invasion in non-small cell lung cancer.Quantitative imaging in medicine and surgery · 2025Article
- Validation for revision of the stage IIIA(T1N2) in the forthcoming ninth edition of the TNM classification for lung cancer.BMC cancer · 2025Article
- Middle lobe tumors and lymphovascular invasion as independent predictors of recurrence-free survival in stage I NSCLC.BMC pulmonary medicine · 2025Article
- External validation of pathological T adjustments in the ninth edition of the pleural mesothelioma tumor-node-metastasis classification.Frontiers in oncology · 2025Article
- Machine learning-based prognostic modeling for locally advanced non-small cell lung cancer treated with immuno-radiotherapy.Frontiers in pharmacology · 2025Article
- Case Report: Controversies in managing pulmonary enteric adenocarcinoma: reflections from an early-stage case.Frontiers in oncology · 2025Article
- Machine Learning Models to Predict Bone Metastasis Risk in Patients With Lung Cancer.Cancer medicine · 2024Article
- Prognostic evaluation of stage I lung adenocarcinoma based on systematic inflammatory response.JNCI cancer spectrum · 2023Article
- Occult lymph node metastasis is not a favorable factor for resected NSCLC patients.BMC cancer · 2023Article
- Investigation of the non-small cell lung cancer patients with bronchus involvements: A population-based study.The clinical respiratory journal · 2023Article
- Is prior cancer history a hindrance for non-small cell lung cancer patients to participate in clinical trials?BMC cancer · 2023Article
- Reconsidering the T category for the T3 non-small cell lung cancer with additional tumor nodules in the same lobe: A population-based study.Frontiers in oncology · 2023Article
- A clinical risk model for assessing the survival of patients with stage IA-IIA non-small cell lung cancer after surgery.Journal of thoracic disease · 2022Article
- Lymphovascular invasion: A non-sized T descriptor for stage IA non-small cell lung cancer.Thoracic cancer · 2022Article
- Stacking Model-Based Preoperative Prediction of Lymphovascular Invasion in Lung Adenocarcinoma by Integrating Intratumoral Heterogeneity Score and Clinicoradiological Features: A Multicenter Study.Technology in cancer research & treatmentArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundLymphovascular invasion (LVI) has not been included in the tumor-node-metastasis (TNM) staging manual of non-small-cell lung cancer (NSCLC). We aimed to investigate the predictive value of LVI on stage IA NSCLC and proposed a method of incorporating LVI into the T category based on the latest TNM staging manual.
methodsThe least absolute shrinkage and selection operator (LASSO)-penalized Cox multivariable regression model was performed to identify prognostic factors. The Kaplan-Meier method was used to compare overall survival (OS) and disease-free survival (DFS) between groups. Propensity score matching (PSM) was used to minimize bias.
resultsA total of 1452 eligible stage I NSCLC cases (stage IA without LVI, 1022 cases; stage IA with LVI, 120 cases; stage IB, 310 cases) were included. LASSO-penalized multivariable Cox analysis revealed that LVI was an independent prognostic factor for both OS and DFS. Survival analysis demonstrated that the survivals of stage IA NSCLCs without LVI were better than those of stage IA with LVI and stage IB NSCLCs. In the matched cohort, the survivals of stage IA NSCLCs with LVI were comparable to those of stage IB NSCLCs.
conclusionsStage IA NSCLCs with LVI and stage IB NSCLCs had similar survivals, and we proposed that LVI might be a non-sized T descriptor that upstaged stage IA diseases to stage IB.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.